Lupus drug Benlysta has been approved by the Food and Drug Administration, becoming the first new lupus drug approved in 56 years.
The intravenous drug was developed by Maryland-based Human Genome Sciences (NASDAQ:HGSI) and GlaxoSmithKline (NYSE:GSK), the British pharmaceutical giant which maintains its American headquarters in Research Triangle Park, North Carolina.
Lupus is an autoimmune disease, affecting primarily women, in which the body attacks healthy tissues. Benlysta works by inhibiting a protein, in turn reducing the number of abnormal cells thought to be a problem in lupus.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Benlysta has been in development for more than 15 years. Discovered by HGS in 1996, the company entered into a co-development and commercialization agreement with GSK 10 years later. Some industry observers have said the drug could become a blockbuster.
But tests show that the drug doesn’t work on everyone. In two clinical studies, African American patients and patients of African heritage did not appear to respond to treatment with the drug. No definitive conclusion was reached and to address this concern. HGS and GSK will conduct additional studies.
Related articles
- GSK HIV drug poses no increased heart attack risk, FDA says (medcitynews.com)
- GSK epilepsy drug gets European OK; U.S. regulators want more details (medcitynews.com)
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
